Free Trial

Grace Therapeutics Q3 2025 Earnings Report

Grace Therapeutics logo
$2.31 +0.03 (+1.32%)
As of 12:34 PM Eastern

Grace Therapeutics EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Grace Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Grace Therapeutics Announcement Details

Quarter
Q3 2025
Time
Before Market Opens

Conference Call Resources

Remove Ads

Grace Therapeutics Earnings Headlines

Elon Tax Shock?
Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.
GRCE: STRIVE-ON Results Reported
See More Grace Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Grace Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grace Therapeutics and other key companies, straight to your email.

About Grace Therapeutics

Grace Therapeutics (NASDAQ:GRCE) Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

View Grace Therapeutics Profile

More Earnings Resources from MarketBeat